MARKET

CATB

CATB

Catabasis Pharms
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.708
+0.038
+2.28%
Opening 15:19 07/28 EDT
OPEN
1.660
PREV CLOSE
1.670
HIGH
1.709
LOW
1.650
VOLUME
181.42K
TURNOVER
--
52 WEEK HIGH
8.59
52 WEEK LOW
1.250
MARKET CAP
151.20M
P/E (TTM)
-0.1870
1D
5D
1M
3M
1Y
5Y
Catabasis Pharmaceuticals To Present At Ladenburg Thalmann 2021 Healthcare Conference
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today announced that Jill C. Milne, Ph.D., Chief Executive Officer, will present a corporate overview and provide information on its lead program QLS-215, which is in preclinical d...
Business Wire · 07/07 12:00
2 Biotech Stocks Wall Street Predicts Will Rally By More Than 150%
StockNews.com · 07/06 10:21
BRIEF-Catabasis Enters Agreement With Jefferies Relating To Sale Of Shares
reuters.com · 06/30 21:08
12 Health Care Stocks Moving In Wednesday's After-Market Session
Gainers
Benzinga · 06/30 20:49
Intellia Therapeutics, Anavex Life Sciences lead premarket gainers
Intellia Therapeutics (NTLA) +58%. after releasing interim data from a phase 1 trial of a CRISPR candidate.Marin Software Incorporated (MRIN) +38%.ReShape Lifesciences (RSLS) +34%.Anavex Life Sciences (AVXL) +24% after after ANAVEX2-73
Seekingalpha · 06/28 12:21
48 Biggest Movers From Yesterday
Gainers Gaucho Group Holdings, Inc. (NASDAQ: VINO) shares jumped 95.1% to close at $7.98 on Wednesday. Gaucho Group highlighted the launch of its Amazon Storefront.
Benzinga · 06/17 09:07
STSA, AXLA, CVAC and CRBP among after-hours movers
Gainers: [[STSA]] +17.8%. [[CLVS]] +6.4%. [[AXLA]] +5.5%. [[RUN]] +4.1%. [[STRR]] +3.1%.Losers: [[CVAC]] -49.7%. [[CATB]] -4.9%. [[CRBP]] -3.8%. [[LXRX]] -3.8%. [[APRE]] -3.5%.
Seekingalpha · 06/16 21:39
Why Kindred Biosciences, Aprea, Catabasis And Inhibikase Are Moving Today
Kindred Biosciences, Inc. (NASDAQ: KIN), Aprea Therapeutics, Inc. (NASDAQ: APRE), Catabasis Pharmaceuticals, Inc.
Benzinga · 06/16 16:30
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CATB. Analyze the recent business situations of Catabasis Pharms through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CATB stock price target is 5.50 with a high estimate of 6.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 77
Institutional Holdings: 14.37M
% Owned: 16.24%
Shares Outstanding: 88.52M
TypeInstitutionsShares
Increased
21
978.99K
New
15
6.00M
Decreased
18
1.02M
Sold Out
15
1.26M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.63%
Pharmaceuticals & Medical Research
+2.07%
Key Executives
Non-Executive Chairman/Independent Director
Kenneth Bate
President/Chief Executive Officer/Co-Founder/Director
Jill Milne
Chief Financial Officer
Noah Clauser
Chief Scientific Officer
Andrew Nichols
General Counsel
Benjamin Harshbarger
Other
Andrew Komjathy
Director
Jonathan Violin
Independent Director
Joanne Beck
Independent Director
Fred Callori
Independent Director
Hugh Cole
Independent Director
Michael Kishbauch
Independent Director
Gregg Lapointe
No Data
About CATB
Catabasis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics. The Company’s lead product candidate is edasalonexent, an oral small molecule that inhibits nuclear factor kappa-light-chain-enhancer of activated B cells, in development for the treatment of Duchenne muscular dystrophy (DMD). In addition to edasalonexent, the Company has developed CAT-5571 as a potential treatment for cystic fibrosis (CF). CAT-5571 is an oral small molecule that is designed to activate autophagy, a mechanism for recycling cellular components and digesting pathogens, which is important for host defenses and is depressed in CF. The Company’s Safely Metabolized and Rationally Targeted (SMART) is a linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.

Webull offers kinds of Catabasis Pharmaceuticals Inc stock information, including NASDAQ:CATB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CATB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CATB stock methods without spending real money on the virtual paper trading platform.